Results 121 to 130 of about 6,220 (214)

Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. [PDF]

open access: yesClin Pharmacol Ther, 2017
Liu C   +21 more
europepmc   +1 more source

Farmakogenetiikka saapuu klinikkaan [PDF]

open access: yes, 2016
English summaryPeer ...
Elenius, Klaus   +3 more
core  

[Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites].

open access: yesAnales de pediatria (Barcelona, Spain : 2003), 2009
Individualised doses of azathioprine (AZA) may be prescribed by monitoring the levels of the enzyme thiopurine methyltransferase (TPMT). The measurements of thiopurine metabolites of AZA, 6-thioguanine (6-TGN) and 6-methylmercaptopurine (6-MMP), have also been reported as new markers of AZA activity.To describe TPMT phenotype in our population and to ...
M, Alvarez Beltran   +4 more
openaire   +1 more source

Integration of a standardized pharmacogenomic platform for clinical decision support at Boston Children's Hospital [PDF]

open access: yes, 2012
Brownstein, Catherine A.   +7 more
core   +1 more source

Frequency of thiopurine methyltransferase variants and exploratory predictors of azathioprine-induced leukopenia in Saudi patients with inflammatory bowel disease. [PDF]

open access: yesSaudi J Gastroenterol
Meeralam YK   +7 more
europepmc   +1 more source

Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease.

open access: yesAnnals of gastroenterology
Azathioprine (AZA) and 6-mercaptopurine (6MP) are used in the treatment of pediatric inflammatory bowel disease (IBD). Genetic variations in thiopurine S-methyltranfarase (TPMT) gene have been correlated with enzyme activity and with the occurrence of adverse events to AZA and 6MP.
Muaria, Gazouli   +6 more
openaire   +1 more source

Home - About - Disclaimer - Privacy